Contact Us

CleanCap® Reagent AG - (N-7113)

CleanCap® Reagent AG for co-transcriptional capping of mRNA,m7G(5')ppp(5')(2'OMeA)pG
In stock
default
N-7113
Product SKU Unit Size Price Qty
N-7113-1 1 µmole
$125.00
N-7113-5 5 µmole
$598.00
N-7113-10 10 µmole
$1,123.00
N-7113-100 100 µmole
$9,152.00

0

Description

CleanCap® Reagent AG is TriLink’s patented co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency.

PLEASE NOTE: CleanCap Reagent AG requires an AG initiator. To learn more, please review the Product Insert below.

Our CleanCap reagents are available in “Research Use” grade as well as GMP-grade “For Further Processing.” GMP product is manufactured in accordance with ISO 9001:2015 and Quality Standards as defined in a GMP Quality Agreement.

To learn more visit: https://www.trilinkbiotech.com/gmp-reagents

Product details
Catalog No N-7113
Purity ≥95% by AX-HPLC
Extinction Coefficient 30,539 Lmol-1cm-1 at 255 nm
Molecular Formula C32H43N15O24P4 (free acid)
Molecular Weight 1145.60 g/mole (free acid)
Salt Form Na+
Concentration 100 mM
Buffer H2O
Recommended Storage -20°C or below
Other Name(s) CleanCap® Reagent AG for co-transcriptional capping of mRNA,m7G(5')ppp(5')(2'OMeA)pG
Application CRISPR, In vitro Transcription, Recombinases, TALENS, Transposases, Vaccine Development, Zinc Finger Nucleases
Backbone 5'-5'-Triphosphate
Base Analog(s) Adenosine, Guanosine
Nucleotide Category Cap analogs
Cap Analogs CleanCap Cap Analogs
Technical documents

N-7113 Safety Data Sheet

CleanCap AG Reagent (N-7113) Product Insert

Products faqs

Ask an Expert

Certificate of analysis

CoA search tool

Intellectual property

CleanCap capping technology For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license. Patents and patent pending, see trilinkbiotech.com/legal-notices.

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.

TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.

References
  1. Jiang, T;Henderson, JM;Coote, K;Cheng, Y;Valley, HC;Zhang, XO;Wang, Q;Rhym, LH;Cao, Y;Newby, GA;Bihler, H;Mense, M;Weng, Z;Anderson, DG;McCaffrey, AP;Liu, DR;Xue, W; . Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope
  2. Tusup, M;L . mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma
  3. Yu, D;Kaur, G;Blumenthal, RM;Zhang, X;Cheng, X; . Enzymatic characterization of three human RNA adenosine methyltransferases reveals diverse substrate affinities and reaction optima
  4. Li, Q;Ren, J;Liu, W;Jiang, G;Hu, R; . CpG Oligodeoxynucleotide Developed to Activate Primate Immune Responses Promotes Antitumoral Effects in Combination with a Neoantigen-Based mRNA Cancer Vaccine
  5. Dobie?y?ska, A;Miszkiewicz, J;Dar?ynkiewicz, ZM;Tyras, M;Stankiewicz-Drogo?, A;Trylska, J;Dar?ynkiewicz, E;Grzela, R; . Development of bis-ANS-based modified fluorescence titration assay for IFIT/RNA studies
  6. Hashimoto, K;Kodama, A;Ohira, M;Kimoto, M;Nakagawa, R;Usui, Y;Ujihara, Y;Hanashima, A;Mohri, S; . Transient induction of cell cycle promoter Fam64a improves cardiac function through regulating Klf15-dependent cardiomyocyte differentiation in mice
  7. Chen, PJ;Hussmann, JA;Yan, J;Knipping, F;Ravisankar, P;Chen, PF;Chen, C;Nelson, JW;Newby, GA;Sahin, M;Osborn, MJ;Weissman, JS;Adamson, B;Liu, DR; . Enhanced prime editing systems by manipulating cellular determinants of editing outcomes
  8. Anzalone, AV;Gao, XD;Podracky, CJ;Nelson, AT;Koblan, LW;Raguram, A;Levy, JM;Mercer, JAM;Liu, DR; . Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing
  9. Wang, H;Alarc . Genetically engineered and enucleated human mesenchymal stromal cells for the targeted delivery of therapeutics to diseased tissue
  10. Parhiz, H;Brenner, JS;Patel, P;Papp, TE;Shahnawaz, H;Li, Q;Shi, R;Zamora, M;Yadegari, A;Marcos-Contreras, OA;Natesan, A;Pardi, N;Shuvaev, VV;Kiseleva, R;Myerson, J;Uhler, T;Riley, RS;Han, X;Mitchell, MJ;Lam, K;Heyes, J;Weissman, D;Muzykantov, V; . Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)
  11. Whitley, J;Zwolinski, C;Denis, C;Maughan, M;Hayles, L;Clarke, D;Snare, M;Liao, H;Chiou, S;Marmura, T;Zoeller, H;Hudson, B;Peart, J;Johnson, M;Karlsson, A;Wang, Y;Nagle, C;Harris, C;Tonkin, D;Fraser, S;Capiz, L;Zeno, CL;Meli, Y;Martik, D;Ozaki, DA;Caparoni, A;Dickens, JE;Weissman, D;Saunders, KO;Haynes, BF;Sempowski, GD;Denny, TN;Johnson, MR; . Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials
  12. Medina-Mag . mRNA Vaccine Protects against Zika Virus
  13. Moradian, H;Roch, T;Anthofer, L;Lendlein, A;Gossen, M; . Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages
  14. Wang, X;Wong, LM;McElvain, ME;Martire, S;Lee, WH;Li, CZ;Fisher, FA;Maheshwari, RL;Wu, ML;Imun, MC;Murad, R;Warshaviak, DT;Yin, J;Kamb, A;Xu, H; . A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy
  15. Nelson, JW;Randolph, PB;Shen, SP;Everette, KA;Chen, PJ;Anzalone, AV;An, M;Newby, GA;Chen, JC;Hsu, A;Liu, DR; . Engineered pegRNAs improve prime editing efficiency
  16. Packer, M;Chowdhary, V;Lung, G;Cheng, L;Aratyn-Schaus, Y;Leboeuf, D;Smith, S;Shah, A;Chen, D;Zieger, M;Cafferty, B;Yan, B;Ciaramella, G;Gregoire, F;Mueller, C; . Evaluation of Cytosine Base Editing and Adenine Base Editing as a Potential Treatment for Alpha-1 Antitrypsin Deficiency
  17. Jensen, TI;Mikkelsen, NS;Gao, Z;Fo . Targeted regulation of transcription in primary cells using CRISPRa and CRISPRi
  18. Alishetty, S;Carrasco, M;Alameh, M;Paige, M;Said, H;Wright, L;Narayanan, A;Alem, F;Hernandez, K;Gillevet, P;Soliman, O;Hicks, P;Manzoni, T;Bates, P;Stephens-Shields, A;Cleveland, T;Grishaev, A;Weissman, D;Buschmann, M; . Novel lipid nanoparticle provides potent SARS-CoV-2 mRNA vaccine at low dose with low local reactogenicity, high thermostability and limited systemic biodistribution
  19. Sun, H;Li, K;Zhang, X;Liu, J;Zhang, M;Meng, H;Yi, C; . m6Am-seq reveals the dynamic m6Am methylation in the human transcriptome
  20. Werder, R;Kaserman, J;Packer, M;Lindstrom-Vautrin, J;Villacorta-Martin, C;Young, L;Aratyn-Schaus, Y;Gregoire, F;Wilson, A; . Adenine Base Editing Reduces Misfolded Protein Accumulation and Toxicity in Alpha-1 Antitrypsin Deficient Patient iPSC-Hepatocytes
  21. Haabeth, O;Lohmeyer, J;Sallets, A;Blake, T;Sagiv-Barfi, I;Czerwinski, D;McCarthy, B;Powell, A;Wender, P;Waymouth, R;Levy, R; . An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory
Show more